FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2409478265> ?p ?o ?g. }

• W2409478265 endingPage "14" @default.
• W2409478265 startingPage "601" @default.
• W2409478265 abstract "Cyclazocine is a benzomorphan derivative, considered as a mixed kappa and and sigma opioid receptor agonist. In experimental study with rats, cyclazocine is known to increase locomotor activity and to produce a bizarre behavioral syndrome including head swaying, backward walking, circling. The present study was undertaken to investigate the effects of various drugs modifying the serotoninergic neuronal systems, upon the locomotor activity and the abnormal behaviors induced by cyclazocine. Pretreatment with p-chlorophenylalanine (PCPA, 400 mg/kg, 72, 48, 24 hr) resulted in an inhibition of the three abnormal behaviors. Pretreatment with p-chloromethylamphetamine (PCMA, 15 mg/kg, 24 hr) antagonized head swaying, backward walking and markedly enhanced locomotor activity. In the contrary, pretreatment with PCMA (2.5 mg/kg, 15 min) resulted in enhanced abnormal behavioral responses to cyclazocine. L-tryptophan (50 mg/kg), 5-hydroxytryptophan (5-HTP, 50 mg/kg), or pargyline (50 mg/kg) inhibited abnormal behaviors and decreased locomotor activity. Serotonin antagonists with affinity fir both 5-HT1 and 5-HT2 receptors, metergoline (0.25-1 mg/kg), methysergide (1-5 mg/kg), amitriptyline (5-20 mg/kg), dl-propranolol (10-40 mg/kg) blocked head swaying and backward walking; only methysergide inhibited circling. All these drugs, except methysergide, markedly enhanced the cyclazocine-induced locomotor activity. In contrast, ketanserine (0.5-2 mg/kg) and pirenperone (0.05-0.2 mg/kg), serotonin antagonists with selective affinity for 5-HT2 receptors had no effects on the abnormal behaviors and locomotor activity. Taken together, these results suggest that a serotoninergic mediation is involved in the cyclazocine-induced abnormal behaviors, and that serotonin exerts an inhibitory control on the locomotor activity produced by the drug. These effects are probably associated with 5-HT1 receptors. Further experiments have shown that the drugs having being able to potentiate cyclazocine-induced locomotor activity, similarly potentiate the locomotor activity induced by levallorphan, morphinan derivative with cyclazocine-like properties but do not enhance the hyperactivity produced by a low dose of morphine. The data reported here, provide a contribution to the informations concerning the neuromediation of the effects of mixed kappa and sigma agonists and allow to compare the mechanism of action of cyclazocine with those of other psychotomimetic drugs." @default.
• W2409478265 created "2016-06-24" @default.
• W2409478265 creator A5018388006 @default.
• W2409478265 creator A5033622496 @default.
• W2409478265 creator A5061079159 @default.
• W2409478265 date "1986-10-01" @default.
• W2409478265 modified "2023-09-23" @default.
• W2409478265 title "[The role of serotonin in the behavioral changes induced in the rat by cyclazocine]." @default.
• W2409478265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3560971" @default.
• W2409478265 hasPublicationYear "1986" @default.
• W2409478265 type Work @default.
• W2409478265 sameAs 2409478265 @default.
• W2409478265 citedByCount "2" @default.
• W2409478265 crossrefType "journal-article" @default.
• W2409478265 hasAuthorship W2409478265A5018388006 @default.
• W2409478265 hasAuthorship W2409478265A5033622496 @default.
• W2409478265 hasAuthorship W2409478265A5061079159 @default.
• W2409478265 hasConcept C126322002 @default.
• W2409478265 hasConcept C134018914 @default.
• W2409478265 hasConcept C170493617 @default.
• W2409478265 hasConcept C185592680 @default.
• W2409478265 hasConcept C2775864247 @default.
• W2409478265 hasConcept C2776120623 @default.
• W2409478265 hasConcept C2777448245 @default.
• W2409478265 hasConcept C2778938600 @default.
• W2409478265 hasConcept C2781005078 @default.
• W2409478265 hasConcept C37000724 @default.
• W2409478265 hasConcept C53910766 @default.
• W2409478265 hasConcept C55493867 @default.
• W2409478265 hasConcept C71924100 @default.
• W2409478265 hasConcept C98274493 @default.
• W2409478265 hasConceptScore W2409478265C126322002 @default.
• W2409478265 hasConceptScore W2409478265C134018914 @default.
• W2409478265 hasConceptScore W2409478265C170493617 @default.
• W2409478265 hasConceptScore W2409478265C185592680 @default.
• W2409478265 hasConceptScore W2409478265C2775864247 @default.
• W2409478265 hasConceptScore W2409478265C2776120623 @default.
• W2409478265 hasConceptScore W2409478265C2777448245 @default.
• W2409478265 hasConceptScore W2409478265C2778938600 @default.
• W2409478265 hasConceptScore W2409478265C2781005078 @default.
• W2409478265 hasConceptScore W2409478265C37000724 @default.
• W2409478265 hasConceptScore W2409478265C53910766 @default.
• W2409478265 hasConceptScore W2409478265C55493867 @default.
• W2409478265 hasConceptScore W2409478265C71924100 @default.
• W2409478265 hasConceptScore W2409478265C98274493 @default.
• W2409478265 hasIssue "4" @default.
• W2409478265 hasLocation W24094782651 @default.
• W2409478265 hasOpenAccess W2409478265 @default.
• W2409478265 hasPrimaryLocation W24094782651 @default.
• W2409478265 hasRelatedWork W1971340305 @default.
• W2409478265 hasRelatedWork W1972147306 @default.
• W2409478265 hasRelatedWork W1977605904 @default.
• W2409478265 hasRelatedWork W1979162154 @default.
• W2409478265 hasRelatedWork W2024525910 @default.
• W2409478265 hasRelatedWork W2054184534 @default.
• W2409478265 hasRelatedWork W2071232880 @default.
• W2409478265 hasRelatedWork W2079308517 @default.
• W2409478265 hasRelatedWork W2160769306 @default.
• W2409478265 hasRelatedWork W2409478265 @default.
• W2409478265 hasVolume "17" @default.
• W2409478265 isParatext "false" @default.
• W2409478265 isRetracted "false" @default.
• W2409478265 magId "2409478265" @default.
• W2409478265 workType "article" @default.